Literature DB >> 21785264

Tissue-based immune monitoring I: tumor core needle biopsies allow in-depth interrogation of the tumor microenvironment.

Andrea R Hagemann1, Mark Cadungog, Ian S Hagemann, Rachel Hammond, Sarah F Adams, Christina S Chu, Steven C Rubin, Lin Zhang, Kathakali Addya, Michael J Birrer, Phyllis A Gimotty, George Coukos.   

Abstract

We sought to assess the feasibility and reproducibility of performing tissue-based immune characterization of the tumor microenvironment using CT-compatible needle biopsy material. Three independent biopsies were obtained intraoperatively from one metastatic epithelial ovarian cancer lesion of 7 consecutive patients undergoing surgical cytoreduction using a 16-gauge core biopsy needle. Core specimens were snap-frozen and subjected to immunohistochemistry (IHC) against human CD3, CD4, CD8, and FoxP3. A portion of the cores was used to isolate RNA for 1) real-time quantitative (q)PCR for CD3, CD4, CD8, FoxP3, IL-10 and TGF-beta, 2) multiplexed PCR-based T cell receptor (TCR) CDR3 Vβ region spectratyping, and 3) gene expression profiling. Pearson's correlations were examined for immunohistochemistry and PCR gene expression, as well as for gene expression array data obtained from different tumor biopsies. Needle biopsy yielded sufficient tissue for all assays in all patients. IHC was highly reproducible and informative. Significant correlations were seen between the frequency of CD3+, CD8+ and FoxP3+ T cells by IHC with CD3ε, CD8A, and FoxP3 gene expression, respectively, by qPCR (r=0.61, 0.86, and 0.89; all p< 0.05). CDR3 spectratyping was feasible and highly reproducible in each tumor, and indicated a restricted repertoire for specific TCR Vβ chains in tumor-infiltrating T cells. Microarray gene expression revealed strong correlation between different biopsies collected from the same tumor. Our results demonstrate a feasible and reproducible method of immune monitoring using CT-compatible needle biopsies from tumor tissue, thereby paving the way for sophisticated translational studies during tumor biological therapy.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21785264      PMCID: PMC3173733          DOI: 10.4161/cbt.12.4.16951

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN: 1538-4047            Impact factor:   4.742


  29 in total

Review 1.  Assays for monitoring cellular immune responses to active immunotherapy of cancer.

Authors:  T M Clay; A C Hobeika; P J Mosca; H K Lyerly; M A Morse
Journal:  Clin Cancer Res       Date:  2001-05       Impact factor: 12.531

2.  Prognostic significance of activated CD8(+) T cell infiltrations within esophageal carcinomas.

Authors:  K Schumacher; W Haensch; C Röefzaad; P M Schlag
Journal:  Cancer Res       Date:  2001-05-15       Impact factor: 12.701

3.  Proliferative activity of intratumoral CD8(+) T-lymphocytes as a prognostic factor in human renal cell carcinoma: clinicopathologic demonstration of antitumor immunity.

Authors:  O Nakano; M Sato; Y Naito; K Suzuki; S Orikasa; M Aizawa; Y Suzuki; I Shintaku; H Nagura; H Ohtani
Journal:  Cancer Res       Date:  2001-07-01       Impact factor: 12.701

4.  Ex vivo expansion of polyclonal and antigen-specific cytotoxic T lymphocytes by artificial APCs expressing ligands for the T-cell receptor, CD28 and 4-1BB.

Authors:  Marcela V Maus; Anna K Thomas; Debra G B Leonard; David Allman; Kathakali Addya; Katia Schlienger; James L Riley; Carl H June
Journal:  Nat Biotechnol       Date:  2002-02       Impact factor: 54.908

5.  Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival.

Authors:  Tyler J Curiel; George Coukos; Linhua Zou; Xavier Alvarez; Pui Cheng; Peter Mottram; Melina Evdemon-Hogan; Jose R Conejo-Garcia; Lin Zhang; Matthew Burow; Yun Zhu; Shuang Wei; Ilona Kryczek; Ben Daniel; Alan Gordon; Leann Myers; Andrew Lackner; Mary L Disis; Keith L Knutson; Lieping Chen; Weiping Zou
Journal:  Nat Med       Date:  2004-08-22       Impact factor: 53.440

6.  Immunization with a P53 synthetic long peptide vaccine induces P53-specific immune responses in ovarian cancer patients, a phase II trial.

Authors:  Ninke Leffers; Annechien J A Lambeck; Marloes J M Gooden; Baukje-Nynke Hoogeboom; Rinze Wolf; Ineke E Hamming; Bouke G Hepkema; Pax H B Willemse; Barbara H W Molmans; Harry Hollema; Jan W Drijfhout; Willem J Sluiter; A Rob P M Valentijn; Loraine M Fathers; Jaap Oostendorp; Ate G J van der Zee; Cornelis J Melief; Sjoerd H van der Burg; Toos Daemen; Hans W Nijman
Journal:  Int J Cancer       Date:  2009-11-01       Impact factor: 7.396

7.  Cancer immunotherapy: moving beyond current vaccines.

Authors:  Steven A Rosenberg; James C Yang; Nicholas P Restifo
Journal:  Nat Med       Date:  2004-09       Impact factor: 53.440

8.  Intraepithelial T cells and tumor proliferation: impact on the benefit from surgical cytoreduction in advanced serous ovarian cancer.

Authors:  Sarah F Adams; Douglas A Levine; Mark G Cadungog; Rachel Hammond; Andrea Facciabene; Narciso Olvera; Stephen C Rubin; Jeff Boyd; Phyllis A Gimotty; George Coukos
Journal:  Cancer       Date:  2009-07-01       Impact factor: 6.860

9.  Therapeutic vaccination with an interleukin-2-interferon-gamma-secreting allogeneic tumor vaccine in patients with progressive castration-resistant prostate cancer: a phase I/II trial.

Authors:  Thomas H Brill; Hubert R Kübler; Heike Pohla; Alexander Buchner; Falko Fend; Tibor Schuster; Heiner van Randenborgh; Roger Paul; Tania Kummer; Christian Plank; Bernd Eisele; Jürgen Breul; Rudolf Hartung; Dolores J Schendel; Bernd Gansbacher
Journal:  Hum Gene Ther       Date:  2009-12       Impact factor: 5.695

10.  Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer.

Authors:  Lin Zhang; Jose R Conejo-Garcia; Dionyssios Katsaros; Phyllis A Gimotty; Marco Massobrio; Giorgia Regnani; Antonis Makrigiannakis; Heidi Gray; Katia Schlienger; Michael N Liebman; Stephen C Rubin; George Coukos
Journal:  N Engl J Med       Date:  2003-01-16       Impact factor: 91.245

View more
  3 in total

1.  A dendritic cell vaccine pulsed with autologous hypochlorous acid-oxidized ovarian cancer lysate primes effective broad antitumor immunity: from bench to bedside.

Authors:  Cheryl Lai-Lai Chiang; Lana E Kandalaft; Janos Tanyi; Andrea R Hagemann; Gregory T Motz; Nikolaos Svoronos; Kathleen Montone; Gina M Mantia-Smaldone; Lori Smith; Harvey L Nisenbaum; Bruce L Levine; Michael Kalos; Brian J Czerniecki; Drew A Torigian; Daniel J Powell; Rosemarie Mick; George Coukos
Journal:  Clin Cancer Res       Date:  2013-07-09       Impact factor: 12.531

2.  Nondestructive, multiplex three-dimensional mapping of immune infiltrates in core needle biopsy.

Authors:  Steve Seung-Young Lee; Vytautas P Bindokas; Mark W Lingen; Stephen J Kron
Journal:  Lab Invest       Date:  2018-11-06       Impact factor: 5.662

Review 3.  Whole Tumor Antigen Vaccines: Where Are We?

Authors:  Cheryl Lai-Lai Chiang; George Coukos; Lana E Kandalaft
Journal:  Vaccines (Basel)       Date:  2015-04-23
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.